| | | | | | |
|
|||||||
| |||||||
|
SIU TIE S10 Agenda
Speakers and Topics - Link to Speaker Bios and Presentation Abstracts
Panel: “Ideas to Markets: Successful Technology Commercialization.” Representatives from industry, university administration, inventors and investors will provide insight into the technology commercialization process.
TIE - S10 Speaker Bios and Presentation AbstractsDr. William HalfordSIU School of Medicine, Department of Medical Microbiology, Immunology & Cell Biology Dr. Halford is currently an Associate Professor of Medical Microbiology, Immunology & Cell Biology at SIU School of Medicine. He earned his bachelor’s in marine biology and microbiology at the University of California, Santa Barbara, in 1991. He earned his master’s in immunology and doctorate in virology, both at the Louisiana State University Medical Center in New Orleans, in 1994 and 1996 respectively. Halford also completed a postdoctoral fellowship at the University of Pennsylvania in Philadelphia in 2000. Halford has published more than 30 journal articles, editorials, and reviews on herpes virus, his main research interest. He recently received NIH funding for the development of a genital herpes vaccine. Halford is a member of the American Society for Virology, American Society for Microbiology, and American Association of Immunologists. He also received the American Herpes Foundation Stephen L. Sacks Investigator award (2004). Tel: 217.545.4277, Email: whalford@siumed.edu. Presentation Title: Effective Genital Herpes Vaccine Genital herpes is an incurable disease caused by herpes simplex virus 2 (HSV-2). The ICP0 protein of HSV-2 is a viral protein that counteracts the natural interferon response in a host immune system, and thus helps allow HSV-2 to establish and maintain infection. This new technology consists of several live, attenuated HSV-2 strains with ICP0 gene mutations that prevent virulence. These strains are very promising candidates for a safe and effective genital herpes vaccine, especially over current potential vaccines, which are composed of replication-deficient viruses or viral proteins and are ineffective at protecting against HSV-2 diseases. Over 1 billion people worldwide are currently infected with genital herpes. Approximately 10 to 20 million more people will contract the disease each year, making a successful genital herpes vaccine a promising and useful technology. Potential uses for this invention include vaccination, treatment, and control for genital herpes and other HSV diseases. Dr. Debbie MukherjeaSIU School of Medicine, Departments of Pharmacology/Surgery Dr. Mukherjea is currently a Research Assistant Professor of Pharmacology at SIU School of Medicine. She earned her bachelor’s in Microbiology, Chemistry, and Zoology at Mount Carmel College, India, in 1995. She earned her master’s in Medicinal Biochemistry at Kasturba Medical College, India, in 1999. She earned her doctorate in Molecular Biology, Microbiology and Biochemistry at SIU School of Medicine in 2004. Mukherjea has published over 30 journal articles and abstracts from scientific meetings. She recently received an NIH Ruth L. Kirschstein NRSA Individual Fellowship grant to study the potential of transplatin to prevent cisplatin-induced ototoxicity. Mukherjea is a member of American Society for Reproductive Immunology, Association for Research in Otolaryngology, and American Association for the Advancement of Science. Presentation Title: Preventing Ototoxicity Cisplatin is a drug commonly used to treat many types of cancer. One of the dose limiting side effects of this drug is hearing loss and other ototoxicities, caused by an increase in Reactive Oxygen Species (ROS) generation and expression of NOX-3 and Transient Receptor Potential Vanilloid 1 (TRPV1). This technology consists of two compounds that can be administered to counteract this ototoxicity. The first compound is short interfering RNA (siRNA) strands specially designed to reduce TRPV1 and NOX-3, which reduces ROS and prevents hearing loss. The second compound, transplatin, is the stereoisomer of ciapltin and has also recently been shown to prevent cisplatin-induced ototoxicity. Over 1.4 million new cases of cancer were estimated in the U.S. for 2009, which indicates that these compounds have potential to be very useful in improving cancer care. Potential uses include prevention of ototoxicity/nephropathy induced by platinum-containing chemotherapy drugs, noise, or aminoglycoside antibiotics, as well as radiation-induced side effects. Dr. Luke TolleySIUC College of Science, Department of Chemistry and Biochemistry Dr. Luke Tolley is currently an Associate Professor at the SIUC Department of Chemistry and Biochemistry. He earned his bachelor’s degree at Brigham Young University in 1996, and his Ph.D. at University of North Carolina in 2001. He was a Postdoctoral Scholar at Oak Ridge National Labs from 2001-2003. Research in the Tolley lab is bioanalytical and based on chromatography, electrophoresis and mass spectrometry. There are two main areas of research: instrumentation development and biological applications. The instrumentation research focuses on the development of multi-dimensional chromatographic and mass spectrometric analysis tools. These tools are then used for the comprehensive analysis of biological samples to search for new biomarkers and intercellular signalling molecules. Tel: (618) 453-6459, Email: ltolley@chem.siu.edu. Presentation Title: New Tools for Finding Protein Targets It is often the case in working with biological samples that you are trying to isolate and identify a specific protein. This protein could be a drug target or might have some useful function, but finding the protein in a complex sample is very difficult. In this presentation I will present two new methods for performing this type of search. The first, bioassay-guided fractionation, can find a protein with a known function, as demonstrated by the isolation of a cellulose-digesting protein from a novel bacterium. The second method, DIABLA, is designed to find the proteins that interact with a small molecule, such as a drug, from a very complex sample. These two tools allow us to find a protein target if we either know what it does or something with which it interacts. They are much more effective than other, competing methods, and can be used on completely unknown protein targets. Dr. Yong GaoSchool/Dept Affiliation: SIUC College of Science, Department of Chemistry and Biochemistry Dr. Yong Gao is an Associate Professor at SIUC’s Department of Chemistry and Biochemistry. He earned his bachelor’s degree at Wuhan University, China, and his Ph.D. at the University of Alberta, Canada. He completed a postdoctoral fellowship at Harvard Medical School. The central piece of his research work is to develop strategies for the functionalization of the nanometer-sized materials to expand their application potentiality in Biomedical/Chemical Sciences. Tel: (618) 201-0665; email: ygao@megiprocess.com. Presentation Title: Midwest Energy Group: Biofuel Production Abstract: Midwest Energy Group Inc. (MEG) focuses on transitioning novel laboratory technologies developed in the Department of Chemistry and Biochemistry at Southern Illinois University Carbondale into commercial large-scale biofuel production. A pilot plant with an annual production volume of 300,000 gallons based-on MEG’s in-house technologies that convert restaurant’s grease trap wastes into biodiesel has been built and is currently under evaluation in Fort Lauderdale, Florida. A much larger plant (> 10 million gallons/year) will be built in the near future once our pilot tests are completed. During recent months, MEG has launched a new research project aiming at producing the second-generation biodiesel from aquatic algae sources. Our presentation will also include some of our preliminary laboratory results in this area as well. Dr. Bakul DaveSchool/Dept Affiliation: SIUC College of Science, Department of Chemistry and Biochemistry Bio: Dr. Bakul Dave is currently an Associate Professor at the SIUC Department of Chemistry and Biochemistry. He received his bachelor’s degree in chemistry from Bombay University in 1987, and his master’s degree in inorganic chemistry from Indian Institute of Technology, Bombay in 1989. He then went to the University of Houston and obtained his Ph.D. degree in inorganic chemistry in 1993. He then pursued postdoctoral research at UCLA in the Department of Chemistry and Biochemistry, and the Department of Materials Science and Engineering. His research interests include inorganic and materials chemistry especially in the area of smart materials and devices. He has authored several papers in the areas of bioinorganic and materials chemistry. His research has resulted in the design and development of smart glasses with applications in separation, drug delivery, sensors, and coatings, and fabric-care technologies. His research has been featured in several business and trade magazines, and has resulted in several patents related to practical applications of these materials. He is a co-editor of Journal of Sol-Gel Science and Technology. Tel: (618) 453-6545, Email: dave@chem.siu.edu. Presentation Title: Controlled Release Systems for Fabric Care This presentation will focus on technological profile of controlled release system based on silicate glasses made using the sol-gel process. Our multi-patent technology portfolio in controlled release systems is based on three different strategies to achieve externally triggered on-demand release. One approach is based on controlled dissolution of glasses where the rate and extent of dissolution can be precisely controlled from seconds to hours to several days. These materials provide ideal release and delivery systems wherein the release can be triggered by means of moisture and humidity regulation. Another approach is based on using mechanical forces such as agitation induced shearing to trigger release (e.g. in washing machine during normal laundry process). These materials exhibit changes in their framework in response to external stimuli to effect release. The third approach involves use of changes in osmolarity or water content to trigger release. These materials undergo changes in their porosity in response to water content to trigger release. Taken together, these systems provide means of controlled release which are particularly beneficial in fabric and personal care system. Dr. George EngelDr. George Engel is Vice President and Co-Founder of Blendics, LLC. George is also a Professor of Electrical Engineering at Southern Illinois University Edwardsville (SIUE). He received his DSc from Washington University in Electrical Engineering and has an active teaching and research program in the area of integrated circuit design at SIUE. Accomplished in circuit design, he co-invented Magtek's MagneprintTM technology; helped develop the Intellihead ASIC for use in credit card readers; was involved in the development of the AUDIOscreener, a portable instrument used to screen infants for hearing impairments; and played an important role in the development of a series of low-power analog circuits for use in an early digital hearing aid. In 1991 he co-founded LoCAT, Inc., a company specializing in computer-assisted tracking systems. He has published widely and has nine patents. Phone: (618) 650-2806, Email: gengel@siue.edu. Presentation Title: EDA Tools for Reducing the Design Time of Integrated Circuits Blended Integrated Circuit Systems (Blendics, LLC) is based in St. Louis, MO and was founded in July 2007. The company is an outgrowth of collaborative research conducted at SIUE and Washington University. Blendics is developing revolutionary Electronic Design Automation (EDA) tools called ClosureACE and MetaACE which will greatly shrink the time required to design large, complex “System on Chips” (SoCs) while at the same time increasing the reliability of these systems. The design tools dramatically reduce the time spent by designers verifying that large complex electronic circuits meet all timing constraints. It is estimated that current design practices and design tools will fail by 2015 when transistor counts approach the 15 billion mark. In an EDA industry with a voracious appetite for acquisitions, Blendics products provide an exciting and disruptive solution to an exploding problem which in turn promises significant return on investment opportunities for investors. Dr. Serdar CelikSIUE Department of Mechanical Engineering Dr. Serdar Celik is an Assistant Professor in the Department of Mechanical Engineering at Southern Illinois University Edwardsville (SIUE). After several years of industrial experience on environmentally-friendly cooling technologies, and completion of his PhD education, he joined SIUE in 2007. His research areas include alternative cooling technologies, renewable energy, and green buildings. Celik has over 20 journal and conference papers, and technical reports. He also owns a patent on an environmentally-friendly cooling device for which he received an Industrial Invention Award in 2004. Celik is a member of the Green Roof Environmental Evaluation Network (G.R.E.E.N.) at SIUE, where he focuses on the energy savings of green buildings in heating and air-conditioning seasons and enhancement of green roof insulation properties. Celik is also leading a solar energy project in which self-adjusting photovoltaic panel systems are being built. The ultimate goal of the solar study is to run the alternative cooling systems with solar power to maintain efficient and ozone-friendly systems. Tel: 618-650-2584, E-mail: scelik@siue.edu. Presentation Title: A Combined-Loop Magnetic Refrigerator This invention is related to a magnetic refrigerator where a magnetocaloric material is used which heats up when a magnetic field applied on it and cools down when the magnetic field is removed. In a general reciprocating magnetic refrigerator, a heat transfer fluid which is driven by a circulation pump flows through a heat exchanger-magnetocaloric material assembly and absorbs the heat when the material heats up. Due to space restrictions, heat exchanger designs are limited to compact models. In this invention, the warm and cold side of the cycle are combined using a solenoid valve so that the one single loop is shared by both warm and cold fluids. Hence less space is occupied making it feasible for magnetic refrigeration systems to be applied to domestic refrigerators. Dr. Ken WittSchool/Dept Affiliation: SIUE School of Pharmacy Dr. Ken A. Witt received his Ph.D. in Pharmacology and Toxicology from the University of Arizona, School of Medicine in 2001. He is currently an Assistant Professor in the Southern Illinois University Edwardsville School of Pharmacy, with collaborations within the SIUE, as well as with colleagues at the St. Louis School of Medicine. His current research includes: 1. the investigation of novel somatostatin subtype selective compounds for the treatment of memory loss and dementia; 2. the investigation blood-brain barrier alterations by ischemic stress, with focus on increasing age and estrogen impact. Tel: 618-650-5144, E-mail: kwitt@siue.edu. Presentation Title: Novel Drugs for Treatment of Alzheimer's Disease: Somatostatin Receptor-4 Agonists The treatment of Alzheimer’s Disease (AD) has shown to be an extremely difficult task, as current medications are ineffective in managing long-term symptoms, and do not halt the progression of the disease. The brains of AD sufferers exhibit various pathological features, the most prominent being amyloid or ‘senile’ plaques. Amyloid plaques consist of extracellular deposits of insoluble amyloid-ß peptide (Aß), and act as a pathological trigger culminating in neuronal death and dementia. A promising avenue for treating AD is to enhance the breakdown for such Aß deposits. With this understanding we are investigating the use of novel drugs that may enhance the breakdown of such deposits and reduce the memory loss. Our hope is that such drugs may provide a viable long-term treatment that can prevent disease progression. Dr. Michael ShawSIUE Chemistry Department Dr. Michael Shaw is currently a Professor of Inorganic Chemistry at SIUE. He earned his bachelor’s degree in Chemistry (1st class honors with distinction) at Mount Allison University, Sackville, in 1988. He earned a Ph.D. in Inorganic Chemistry at the University of British Columbia, Vancouver, B.C., Canada, in 1993. He was a Post-doctoral Fellow with Geiger Group, University of Vermont, Chemistry, 1993-1996. Current research includes the chemical and electrochemical properties of organometallic compounds in which an alkyne ligand is pi-bound to a metal atom, with a focus on octahedral d6-metal complexes. Tel: 618-650-3579 E-mail: michsha@siue.edu. Presentation Title: An Inexpensive, Programmable Potentiostat for Teaching and Research Applications Research in fuel cell and solar cell technology requires the use of a "potentiostat", i.e. a device which can measure current output at carefully controlled electrical potentials. Our work has been to use inexpensive, programmable PSOC chips to design and demonstrate working models of digital potentiostats. Inexpensive yet high-quality potentiostats would benefit both research and education applications: hands-on experience with real electrochemical systems from the high-school through college level would lead to a generation with fundamental understanding of how energy-producing cells work. Panel MembersConnie M. ArmentroutDirector, Technology Academic Licensing, Monsanto Company Connie joined Monsanto Company in September of 2001. In the role of Director of Academic Licensing, she drafts and negotiates the various agreements necessary for Monsanto researchers to conduct their research programs. The agreements include material transfer, research, supply agreements, fee for service, Federal, intellectual property option, and license agreements. She also serves as liaison between academic research administration and technology transfer offices and the Monsanto scientists. Prior to joining the Technology Alliances Team at Monsanto, Connie set up the Office of Technology Development for the University of Oklahoma. Before moving to OU, she was the Director of the University Patents & Licensing Office at the University of Missouri System. She had transitioned to the UP&L from the University of Missouri – Columbia Office of Sponsored Programs unit. Robert PatinoDirector of Technology Transfer, SIU School of Medicine Robert Patino is the Director of Technology Transfer at the Southern Illinois University School of Medicine. In this capacity, he serves to evaluate the patentable and commercial merit of discoveries by faculty and staff at the School of Medicine and dedicates his efforts to advancing those discoveries through the commercialization pipeline. He received his BSE in Chemical Engineering from the University of Iowa in 1998 and received his Juris Doctor from DePaul University in 2003. He is a registered patent attorney and has extensive experience in prosecuting intellectual property rights and managing complex licensing agreements. He is also the president of the Illinois Government Bar Association, Chairman of the Jamie Patino Math and Science Scholarship and is an active member on several committee boards. Bill RowePrincipal, The Incubation Factory Bill Rowe is a Principal of TIF-I located in Missouri. He is an accomplished business leader and innovator with a demonstrated track record of growing successful businesses, both inside existing Fortune 500 organizations and as stand-alone companies. Bill has served in a broad range of business development, product commercialization, alliance management and leadership positions in professional services, healthcare and technology markets. Throughout his career, Bill has leveraged proven skills in effective management, consultative sales, strategic marketing and alliance development, combined with a demonstrated success in leading teams to optimize company growth and profitability through constant innovation. At The Incubation Factory, Bill role is to source high-potential opportunities, manage the investment portfolio, provide corporate guidance, and develop long-term partnerships with strategic partners and investors. Bill earned his MBA from St. Louis University and a Bachelor of Science in Business Administration from The University of Tulsa, in Oklahoma. Dr. David LightfootProfessor, SIU Biotechnology and Genomics Dr. Lightfoot has a PhD in Genetics and is a Professor for Biotechnology and Genomics at SIUC. He has been a member of the Department of Plant, Soil and Agricultural Systems at Southern Illinois University since 1991. He is cross-appointed in the Department of Plant Biology and the Department of Biochemistry and Molecular Biology. Currently Dr. Lightfoot is also working on Phytoestrogen manipulated beans, Oil content manipulated beans, and Insect resistant beans. He is Head of the Genomic Science Facility at SIUC. He is an Illinois Humanities Commission Road Scholar. Keynote SpeakersDr. James K. BashkinJames K. Bashkin was born in Iowa City in 1958. He earned a bachelor’s degree at University of California at Irvine in 1977, and a Ph.D. in organometallic chemistry in 1982 at Oxford. He was a Postdoctoral Fellow in R.H. Holm’s group at Harvard. He then took a position at Monsanto, in the Chemical Sciences Department of Corporate Research. During this time (1985-1991), he developed programs on solid-state reference electrodes, a new green chemistry version of nucleophilic aromatic substitution, and catalytic drugs based on functional mimics of ribozymes. Through the efforts of many co-workers, the green chemistry was recently commercialized in Europe by Flexsys, which is a joint venture between Solutia (formerly Monsanto) and Akzo Nobel. He and co-inventor M. K. Stern shared Monsanto’s Thomas and Hochwalt prize for this chemistry. He was appointed to the Editorial Advisory board of Chemical Reviews in 1991, co-chaired the NSF Organometallic Workshop (1988-1990), and has served on an NSF review panel for SBIR grants. In 1991, he joined the chemistry faculty at Washington University as an Assistant Professor. He has continued to pursue bioorganic and bioinorganic approaches to catalytic drugs, and to study the mechanism of RNA transesterification and hydrolysis. He has recently moved back into the green chemistry arena. He was on the varsity modern pentathlon team at Oxford and continues to run and swim when the opportunity arises, but no longer jumps over fences on horseback. The guitar has supplanted the cello as his musical instrument of choice. His family (Jacob, Samuel, and Shelley) form the most important part of his life. Matthew KuligMBA, COO Aisle411 Inc., Serial Entrepreneur A serial entrepreneur, MBA, and executive manager, Matthew brings experience in company formation, market research, financial creation and analysis, Capital raising, competitive strategy, and always a strong passion to new business concepts. Upon receiving his MBA from SIUE, Matthew Co-Founded Global Velocity in 2000 to solve the problem of piracy, identity theft, spam, and viruses over the Internet. He served as President and CEO of the company until 2005 and he served on the Board until 2009. Matthew has been involved in 7 start-up companies to date involving network technology, music, mobile technologies and internet business modeling. Matthew has also served as a Business Manager for a Public Relations company and worked in the Radio and Recording Industry. He has over 25 years of business experience. Matthew has written 3 patents and his patents have issued around the world. He has written and submitted SBIRs and STTRs to various federal agencies. He has also written white papers and articles on his various business products and concepts over the years. A passionate speaker, Matthew will talk about the coming decade of mobile and voice innovations, concepts, businesses and what it takes to be a high-tech entrepreneur in today's economy.
|